

REMARKS

Currently claims 1-43 and 46-48 are pending. Claims 44 and 45 have been canceled. All pending claims have been amended to be consistent with the amended PCT claims and to correct typographical mistakes.


The specification has been amended to correct the duplicative numbering of Table 4 so that the second Table 4 on page 52 has been renumbered Table 5, and subsequently Tables 5-7 on pages 54, 55, and 59, respectively, have been renumbered Tables 6-8.

The specification also has been amended to correct the references to microorganism deposit accession number DSM4393 with references to DSM17158, and to correct the references to microorganism deposit accession number DSM1A423 with references to DSM17159.

Applicants respectfully submit that the present application is in condition for examination and respectfully request the early consideration thereof and the issuance of a Notice of Allowance.

If necessary, the Commissioner is hereby authorized in this, concurrent, and future replies, to charge any fees or credit any overpayment, particularly including any fees required under 37 CFR Sect 1.16 or 1.17, and any necessary extension of time fees, to deposit Account No. 07-1392.

Respectfully submitted:



Alice P. Bradney
Attorney for Applicants
Reg. No. 51,491

Date: May 9, 2007
GlaxoSmithKline Inc.
Corporate Intellectual Property
Five Moore Drive, P.O. Box 13398
Research Triangle Park, NC 27709
Tel. (919) 483-1891
Fax: (919) 483-5730